Friday, May 24, 2013

Alzheimer's Cause Found In Trigger Of Brain Protein Malfunction

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Medical News Today
 
In a new breakthrough to find the cause of Alzheimer's disease, scientists have pinpointed a molecule that appears to trigger a chain reaction of protein malfunction that eventually clogs up and kills brain cells.
The teams, from the University of Cambridge in the UK and Lund University in Sweden, write about their findings in a paper due to be published online first this week in the Proceedings of the National Academy of Sciences.

Tuomas Knowles, one of the study leaders, runs a group based at Cambridge that studies the physical aspects of protein molecule self-assembly. In a statement about the study, he says current therapies for Alzheimer's and
dementia are limited, they don't address the disease, only the symptoms:

"We have to solve what happens at the molecular level before we can progress and have real impact," he adds.

And that is what the researchers on this study did: they dug deep into molecular behavior and produced a detailed map of the pathway that produces the malformed proteins that are at the root of neurodegenerative disorders like Alzheimer's.

They believe their breakthrough is an important step toward earlier diagnosis of neurological disorders like Alzheimer's and Parkinson's.

And by revealing molecular clues about the earliest stages of Alzheimer's, they say the findings also open new avenues for developing drugs that target these pathways in the early stages of the disease.

Misfolding Proteins and Amyloid Fibrils

When proteins made in brain cells start to misfold and take on structures that cause them to malfunction, the end result is neurodegenerative diseases like Alzheimer's.

Proteins are important molecules for carrying out essential jobs in and around cells. To make a protein, the cell assembles amino acids according to patterns encoded in its DNA. The assembled protein is a long thin chain that is then folded into a complex, tightly packed and precise structure so it can carry out its tasks correctly.

Things start to go wrong when proteins misfold. These can then snag surrounding proteins, even if they are normal, producing clumps that can build up to millions of protein molecules, forming unwieldy tendrils called "amyloid fibrils".

Amyloid fibrils are what produce the large protein deposits or "plaques" found in the brains of people with Alzheimer's. These were thought to be the primary cause of the disease, until another senior author of this latest study, Christopher Dobson, a professor of Chemistry at Cambridge, and his team discovered "toxic oligomers" about ten years ago.

Toxic Oligomers and Juvenile Tendrils

When the abnormal amyloid fibrils that lead to plaques start to grow, the tendrils grow outwards around the starting or focal point. This is known as "nucleation".

When these were first discovered, it was thought that the key to the cause of Alzheimer's was this nucleation process. But that is only part of the story.

What this study shows is that once a small but critical amount of malfunctioning protein clumps together, it triggers a runaway chain reaction that leads to rapid formation of new clumps, activating new focal points through "nucleation".

And it appears it is these secondary nucleations that create juvenile tendrils that at first have just a few clusters containing a handful of protein molecules, or "toxic oligomers". (An oligomer, comprising only a few molecular units, is a much shorter version of a polymer, a repeating chain of units that can almost go on for ever).

These "toxic oligomers" are soluble and small enough, unlike the bigger, insoluble and denser plaques (which have more of a knotted polymer structure), to travel around the brain and wreak havoc by interacting harmfully with other molecules. The result is the gradual death of neurons that cause loss of memory and the other known symptoms of dementia.

Before this study scientists knew that toxic oligomers were more likely to be the cause of Alzheimer's, but were mystified about where they came from.

Knowles says:

"We've now established the pathway that shows how the toxic species that cause cell death, the oligomers, are formed. This is the key pathway to detect, target and intervene - the molecular catalyst that underlies the pathology."

Recreating the Crime Scene at the Root of Alzheimer's

The researchers brought together tools commonly used in other areas of chemistry and physics, but this study is the first time they have been used to their full potential to look at misfolding proteins.

"Increasingly, using quantitative experimental tools and rigorous theoretical analysis to understand complex biological processes are leading to exciting and game-changing results," says Knowles.

He explains that they are essentially borrowing tools from chemistry and physics to look at a biomolecular problem: to map the networks of processes and "recreate the crime scene" that is at the molecular root of Alzheimer's.

"With a disease like Alzheimer's, you have to intervene in a highly specific manner to prevent the formation of the toxic agents. Now we've found how the oligomers are created, we know what process we need to turn off," he adds.

In another breakthrough study published recently researchers suggest
new Alzheimer's treatment may come from discovering how plaques lead to tangles.

Written by Catharine Paddock PhD
Copyright: Medical News Today

Wednesday, May 22, 2013

Top activities for those with dementia on Memorial day



Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire




Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

  • Veterans who suffer from various forms of dementia, including Alzheimer disease, often have very specific care needs. It is important that these veterans are cared for by people who understand their condition and have the appropriate instruction and skills. Therefore encourage family members of veterans to gain the training they need to care for their loved one with dementia.

  • For those in nursing homes and other institutions, make sure veterans with dementia are visited often. All people, including those with memory loss, need human contact. They need to be hugged. They need to hear your voice. They may not know you but as long as you know who they are, that's all that matters.

  • Talk to them about their service to our country. Often they will share stories with you because their time in the service made a huge impression on them 

  • Tell them how proud you are of them. Thank them for their service. This is sure to make them feel good. Most likely, it will make them smile

  • Smile with a veteran. Laughter is wonderful medicine.

  • Sing patriotic songs with a veteran with dementia. Often they will be able o sing many familiar songs even though, they may not be able to speak.

  • Read to them. Have them read to you. Large simple statements are best.
  • Share pictures with them, especially large colorful ones

  • Make a visitor's packet for them.

  • For more ideas on things you can do with a veteran or anyone with dementia on this Memorial Day or any day, read the book, Adorable Photographs of Our Baby-Meaningful, Mind-Stimulating Activities and More for the Memory Challenged, 
  • Their Loved Ones, and Involved Professionals 

  • So please remember all our veterans on Memorial Day including those with dementia




Friday, May 10, 2013

Diet may improve Alzheimer's

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

News Fix
 
A study suggests that a high fat, low carbohydrate diet can help improve Alzheimer’s disease in mice.
It’s been previously suggested that a high fat diet may predispose the brain to Alzheimer’s disease, perhaps by clogging up the arteries. Researchers in Colorado seem to be suggesting the opposite – at least from animal studies.

They have been looking at a group of mice with the equivalent of Alzheimer’s disease. Giving the animals a diet that is high in fat, low in carbohydrate, reduces the amount of beta-amyloid, the brain protein deposits which are the hallmarks of Alzheimer’s disease. The researchers explain their results suggesting that insulin and insulin-related growth factor may be involved. In this kind of diet, insulin seems to be able to break up the amyloid deposits. Other studies have looked at fat in the presence of high carbohydrate. When the carbohydrates are reduced, insulin may behave in a more positive way.
 

Wednesday, May 8, 2013

Aspiration Pneumonia Risks Premature Death in Alzheimer's

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Medscape Today
 
Taipei, Taiwan — The risk of dying of aspiration pneumonia among people with Alzheimer's disease and related dementias (ADRD) is higher for men than women and, in the United States, is higher for younger elderly compared with those 85 years or older, according to a survey of death certificates.
Presenting his analysis here at the Alzheimer's Disease International (ADI) 28th International Conference, Tsung-Hsueh Lu, MD, PhD, from the Department of Public Health at National Cheng Kung University Hospital in Tainan, Taiwan, told delegates that death certificates list a disease or condition directly leading to death and then other antecedent conditions as contributing causes, but often those latter causes are lost in analyses.
For example, a death certificate may list sepsis as the direct cause, but if aspiration pneumonia and Alzheimer's disease are listed as antecedent causes, only sepsis may be considered for purposes of vital statistics. So he and a colleague looked for occurrences of listings of aspiration pneumonia, which can be a preventable cause of premature death, with ADRD.
Between 2002 and 2009, 6% of death certificates in the United States and 3.6% of those in Taiwan that listed ADRD as a cause of death also listed aspiration pneumonia.
Table. Aspiration Pneumonia on Death Certificates Listing ADRD (2002 to 2009)
Endpoint United States (n = 2,002,957) (%) Taiwan (n = 9143) (%)
Total6.03.6
Sex  
  Men8.44.5
  Women4.82.8
Age  
  65 - 74 y7.53.2
  75 - 84 y6.63.7
  ≥85 y5.53.6
 
Men in the United States were at a 78% greater risk for aspiration pneumonia if they had ADRD than were women (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.776 - 1.80). Similarly, men in Taiwan were 71% more likely than women there to die with aspiration pneumonia with ADRD (OR, 1.71; 95% CI, 1.36 - 2.14).
Compared with people aged 65 to 74 years in the United States, residents with ADRD had a decreasing risk for aspiration pneumonia as they aged (at 75 to 84 years: OR, 0.92 [95% CI, 0.90 - 0.94]; at ≥85 years: OR, 0.84 [95% CI, 0.82 - 0.86]). An interesting finding that Dr. Lu could not explain was that Taiwan residents trended in the direction of a nonsignificant increased risk with age.
In both countries, the proportion of people dying with aspiration pneumonia and ADRD decreased during the study period, from 6.9% in 2002 to 2003 to 5.0% in 2008 to 2009 in the United States (OR, 0.72 [95% CI, 0.70 - 0.73] for later period vs earlier) and (nonsignificantly) from 3.9% to 3.5% in Taiwan for the same periods (OR, 0.86 [95% CI, 0.63 - 1.17]).
Dr. Lu cautioned that aspiration pneumonia may be underreported as a cause of death, so the true figures may be even higher than that found from death certificates. And in the United States, different states may have different systems for determining and reporting the causes of deaths.
Preventing Premature Death
Aspiration of food is a major cause of pneumonia, but the risk can be reduced. "Speech therapists should be consulted to evaluate the swallowing ability in such a patient, training of the swallowing, or preparing of food to prevent this premature death," Dr. Lu advised.
Session moderator David Troxel, MPH, a long-term care consultant and writer in the field of dementia in Sacramento, California, commented to Medscape Medical News that swallowing issues and food aspiration are recognized as big problems among elderly patients with dementia.
"Where I'd say we aren't doing a good job is I think that families don't know to go to a speech pathologist. Doctors may not think about referring to a speech pathologist who can maybe help with that and assess [the patient]," he said. "Certainly in home settings I doubt families know much about how to prepare foods
 Go to different kinds of puréed foods."
He said he believes families are not getting much support in this area, so problems persist. He suggests that professionals in the elder care field talk to physicians about recognizing problems contributing to aspiration, about referring to speech pathologists, and "to really do more education with the families about different dos and don'ts about food."
Mr. Troxel is a dementia consultant to Atria Senior Living, Home Instead, American Baptist Homes of the West, and Prestige Care, and he previously consulted for Genentech Roche.
Alzheimer's Disease International (ADI) 28th International Conference. Abstract OC024. Presented April 19, 2013.
 

Thursday, May 2, 2013

Alzheimer's Disease Symptoms Reversed in Mice (part 2)

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Scientific American
 
by Gary Stix
 
The study also provides the most compelling evidence to date of how the biggest risk factor for Alzheimer's later in life—having the so-called Apolipoprotein E (APOE) gene, identified in the early 1990s—might yield a strategy for new therapies. The gene for apolipoprotein E comes in three versions, one of which, the e4 variant, confers a significantly higher risk of getting the disease—a roughly 60 percent chance at age 80 for those who carry a copy from both their mother and father, as against a less than 10 percent overall risk at that age in the general population. The gene variant, known informally as the Alzheimer's gene, is common: about 20 percent of the U.S. population has at least one copy. The e4 carriers may be vulnerable to Alzheimer's because they have a diminished ability to clear amyloid, a hypothesis that seems to be reinforced by this Case Western study.
Jumping the gun?
That idea, though, is not universally endorsed. Some experiments have shown that the e4 version may also impair the brain in other ways, perhaps by bollixing the biochemical functioning at the synapses, the connection points between neurons, or by producing toxic fragments of the lipoprotein that damage neurons. If so, increasing the production of this form of apolipoprotein E could actually worsen the pathology of the disease and would complicate greatly bexarotene's development.

This potential hurdle does not dissuade one researcher experienced in Alzheimer's clinical trials. "I am not particularly concerned" about potential toxic effects of extra e4 production, says Paul Aisen of the University of California, San Diego, who heads the Alzheimer's Disease Cooperative Study, which organizes clinical trials for drugs to combat the illness. "If it significantly enhances amyloid clearance and reduces the burden of brain amyloid, there is a good chance it will succeed." David Holtzman, a prominent Alzheimer's researcher from Washington University in Saint Louis, echoes the sentiment about bexarotene's prospects: "I do think it is promising to go into humans."
Landreth and Cramer certainly think so. They have formed a company called ReXceptor Therapeutics that intends to begin a preliminary trial in humans in the next few months to determine whether the drug crosses the blood–brain barrier and clears amyloid, as it does in mice. If those processes occur, clinical trials on the drug's effectiveness in humans could begin even this year, and they would probably last from 18 months to three years. The drug loses patent protection for cancer this year, but Case Western has filed for patents for its use in Alzheimer's.
Many unknowns
Despite their optimism, scientists say it's important not to overplay the progress. After all, drugs that work in mice do not necessarily help humans. Moreover, the genetically engineered version of mice used in this study do not recapitulate every aspect of the human disease. For instance, the mice do not experience the effects of dying neurons (despite having impaired cognition), and they do not go on to develop a hallmark characteristic of a later disease stage in humans—namely, the accretion of so-called tau proteins that seem to abet the killing of nerve cells. "Transgenic mouse experiments have not reliably predicted therapeutic effects in humans," Aisen says, "so caution is essential until human studies confirm target engagement," that is, the removal of amyloid plaques.

And bexarotene does not come without risk: it raises levels of triglycerides, blood fats implicated in cardiovascular disease and diabetes. The Case Western mouse work suggests that Alzheimer's patients may benefit with doses lower than those ingested for cancer treatment, which might produce less of an effect on fat levels. Whether the drug remains effective over time is another question. The levels of amyloid plaques—although not the apparently more toxic soluble form of the peptide—rose after 90 days, a suggestion that the drug may be metabolized differently after ingestion over long periods.
The enthusiasm generated for a mouse study stems from the desperation for new ideas as the number of Alzheimer's cases, now at 5.4 million in the U.S., is expected to more than double by the year 2050 as the nation's demographic profile continues to gray. A better understanding of the disease process—the knowledge that pathology begins 10 or 20 years before the first symptom—has shifted focus toward earlier drug trials. New technologies that combine brain imaging and spinal fluid tests might identify at-risk patients and test new drugs. A relatively inexpensive drug that can be ingested orally, such as bexarotene, could then be prescribed to at-risk but symptom-free patients, who would take them over the course of their lifetimes, like a cholesterol-lowering drug.
As ReXceptor moves forward with its clinical trial plans, it will inevitably have to contend with the demands of the families of Alzheimer's patients. Landreth emphasizes that calling your physician after reading an article like this one is a bad idea. "Don't try this at home," he cautions, "because we don't know we what dose to give, we don't know how frequently to give it, and there are a few nuances to its administration. So one shouldn't be prescribing it off-label." It is also unclear whether a drug like bexarotene would work at a middle or advanced stage of the disease, when neurodegenerative processes have already set in.
Bexarotene's genesis as an Alzheimer's treatment comes as an outgrowth of Landreth's long-time fundamental work on cell receptors. If it succeeds, it will demonstrate that new ideas for treating this seemingly intractable disease may come from beyond the sometimes narrowly focused strategies of large pharmaceutical companies.

Tuesday, April 30, 2013

Alzheimer's Disease Symptoms Reversed in Mice

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Scientific American
 
A cancer drug given to mice eliminates brain-damaging proteins, leading to improved cognition within days, but will it work in humans?
In the study, published online February 9 by Science, researchers from Case Western Reserve University in Cleveland and colleagues used mice genetically engineered to exhibit some of the symptoms of Alzheimer's. Most notably, the mice produced amyloid beta peptides—toxic protein fragments that gum up neurons and lead to cell death—and showed signs of forgetfulness.

Amyloid beta (red areas) peptides clear from the brain of an Alzheimer's mouse after three days of treatment with a cancer drug (right image). Source: AAAS/Science
The Case Western team, led by Gary Landreth, decided to try the drug bexarotene (Targretin), approved in 1999 for cutaneous T cell lymphomas. The team chose this drug because of its long experience working with proteins in the nucleus of brain cells that can induce biochemical processes that affect amyloid beta.
Landreth and his colleagues fed bexarotene to the demented mice, and with just a single dose it lowered the most toxic form of the amyloid beta peptide by 25 percent within six hours, an effect that lasted for up to three days. Mice that were cognitively impaired by the amyloid buildup resumed normal behaviors after 72 hours: They began to crinkle toilet paper placed nearby to make nests, a skill lost as amyloid increased in their brains.
"We have successfully reversed all of the known pathological features and behavioral deficits found in mouse models of Alzheimer's disease," Landreth says. "Never before has anyone observed clearance of amyloid plaques with such speed in mouse models."
Other Alzheimer's researchers hail the work. "I think this is extremely promising," says Samuel Gandy, a professor of neurology and psychiatry at Mount Sinai School of Medicine and associate director of the hospital's Alzheimer's Disease Research Center. "One of the drugs that has been on our wish list for 25 years is a drug that would clear existing amyloid deposits."
"Landreth's paper is impressive," adds Kenneth Kosik, a neuroscientist at the University of California, Santa Barbara. "The effects in mice, including some restoration of cognitive abilities, are dramatic."
Neural sanitation
In a field littered with drug failures, the study offers hope that the strategy of clearing the brain of the toxic peptide can work. Bexarotene does not do so directly, however; instead, it activates retinoid receptors on brain cells that increase production of a fat-protein complex, apolipoprotein E, that helps rid excess amyloid in the fluid-filled space between neurons. It also appears to enhance another cleanup process, called phagocytosis.
Bexarotene functions differently than an amyloid-clearance approach using monoclonal antibodies, which are further down the drug development pipeline. These antibodies bind directly to amyloid and then remove it, but they have sometimes caused fluid to fill brain tissue. Bexarotene may be less likely to cause such swelling. "I think the fact that we're inducing a natural process by turning on these receptors doesn't lend itself to water on the brain," says Paige Cramer, Landreth's graduate student who performed much of the research. Unlike bexarotene, which is taken orally, monoclonals are more troublesome to administer, because they must be delivered intravenously, and if they receive U.S. Food and Drug Administration approval, they would likely be significantly more expensive.

Come back for more

Saturday, April 27, 2013

Alzheimer’s Advance: Gene Could Help to Clear Brain Plaques Responsible for the Disease

Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Time
 
Mapping out how an Alzheimer’s gene works could lead to new treatments.
So far, nearly two dozen genes scattered across four chromosomes have been linked to an increased risk of Alzheimer’s disease. But identifying such genetic risk factors doesn’t mean that researchers fully understand how they contribute to cognitive decline and dementia. And that understanding is often crucial to turning genetic information into effective treatments.
Now a group of scientists report in the journal Neuron that they have pieced together the back story of one gene, known as CD33, that could lead to exciting new ways of removing the amyloid plaques that build up in the brains of Alzheimer’s patients and cause so many problems with memory and cognitive functions.
(MORE: New Research on Understanding Alzheimer’s)
Dr. Rudolph Tanzi, director of the genetics and aging research unit at Massachusetts General Hospital and professor of neurology at Harvard Medical School, and his team first identified CD33 in 2008, and at the time, he says, “We had no idea what this thing did. And in the [scientific research] literature, little was known about it. So we started from scratch.”
Beginning with studies of the where the gene was expressed, he found that a subset of brain cells known as microglia seemed to show high levels of CD33, which makes receptors that pop up on the surface of the cells to bind to neuronal debris, including the residue of inflammatory reactions, and dead and dying nerve cells. CD33 functions as a molecular housekeeper, patrolling the nervous system for any material that doesn’t belong and could impair normal brain function. That includes the deposits of amyloid protein that build up in the brains of Alzheimer’s patients, eventually forming sticky plaques that compromise normal nerve function before destroying them.
(MORE: First Genes Linked to Higher Risk of Alzheimer’s Disease Among African-Americans)
But when Tanzi’s team looked at the brains of patients who had died of Alzheimer’s, they found that CD33 also had a darker side. In patients with a higher burden of amyloid plaques, CD33 also appeared in excess. And so did tons of dead neurons. “At some point, as the amyloid is making the cells sick, and forming tangles as lots of neurons are dying, the microglia put on their battle gear and turn radical, killing whatever they think is attacking the brain,” says Tanzi. “The result is friendly fire, and they start to kill so many neurons that the microglia are now detrimental; they are no longer clearing but they’re rounding up nerve cells and shooting out free radicals and causing a lot of damage.”
Instead of engulfing and removing the amyloid, microglia armed with CD33 were targeting healthy nerves instead. To confirm that, Tanzi’s team conducted a series of tests with cells in culture and in animals, and found that when microglia were stripped of CD33, they went back to performing their housekeeping duties as expected, sniffing out amyloid and pulling the protein out of circulation. Mice genetically engineered to develop Alzheimer’s plaques but without CD33 showed lower levels of amyloid plaques in their brains than animals with the gene, suggesting that the CD33 was clearing the protein away.
(MORE: Genetic Markers May Predict Increased Risk of Alzheimer’s)
That clearance could be the key to alleviating some of the worst symptoms of the disease, experts say, since most people make amyloid protein but for some reason it starts to accumulate as we age. “What we discovered is that CD33 is a key switch so when the switch is off, and it is deactivated, there is more clearance of [amyloid,]” says Tanzi. “If we can now find drugs that inactivate CD33 it should allow more clearance of [amyloid] by the microglial cells.”
His group is already screening compounds to find those that might block CD33 from turning rogue, but the search will have to balance compounds that do a good job of keeping CD33 honest without compromising its ability to seek and destroy real invaders, as it was designed to do. “It’s something we have to keep an eye on for sure,” says Tanzi of the possibility that a CD33 blocker to treat Alzheimer’s could compromise immune functions and make patients more vulnerable to infections or other health issues.
But the discovery could be an important step toward finally developing an effective Alzheimer’s drug treatment, since clearing amyloid plaques could be critical in addressing the deposits of amyloid that mushroom throughout the brain as the disease progresses. “We just need to take advantage of the housekeeping functions of CD33 and entice them to stay helpful and not go crazy,” says Tanzi.
MORE: Two Studies Find Promising New Ways to Detect Alzheimer’s Earlier

 
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info